Independent. No paid rankings. Our evidence grades are never for sale. Where a cosmetic or skincare product passes our review, we may link to it with a disclosed affiliate link. Reviewed weekly Editorial policy Newsletter

Home›Explore peptides›Dalbavancin

Dalbavancin

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 12 September 2026Funding No vendor payment

Dalbavancin (Dalvance) is a real, FDA-approved lipoglycopeptide antibiotic with a genuinely unusual standout feature: a roughly two-week half-life that lets an entire course of treatment be delivered in just one or two IV doses, rather than days of repeated infusions.

Evidence grade A: what kinds of studies support the claims on this page, with limits. It is not a verdict on any product. How we grade

On this page

  1. A vancomycin relative built for a long half-life
  2. The approval and pivotal trials
  3. Safety
  4. Current status

In brief

Should you care? Relevant only in hospital-level skin-infection treatment — but a genuinely notable convenience/adherence story.

The short version

  • A roughly 14-day half-life — a single dose, or two doses a week apart, can cover an entire course of therapy.
  • Approved May 2014, the first drug approved under the FDA's Qualified Infectious Disease Product designation.
  • No boxed warning — a comparatively light safety label relative to some peptide antibiotics this site covers.

A vancomycin relative built for a long half-life

Dalbavancin is a semi-synthetic lipoglycopeptide, mechanistically related to vancomycin and telavancin — it binds the D-Ala-D-Ala terminus of peptidoglycan precursors to block cell-wall cross-linking, with a lipid side chain that anchors it to and helps it accumulate at the bacterial membrane. What actually distinguishes dalbavancin in practice is pharmacokinetics, not mechanism: a terminal half-life of roughly 14 days, unusually long for an antibiotic, meaning a full course of treatment can be delivered as a single 1,500mg dose or as two doses a week apart, rather than daily infusions for a week or more.

The approval and pivotal trials

The FDA approved dalbavancin (as Dalvance) on 23 May 2014 for acute bacterial skin and skin-structure infections — the first drug approved under the Qualified Infectious Disease Product (QIDP) designation created by the GAIN Act to encourage new antibiotic development. The pivotal DISCOVER trial program (Boucher et al., N Engl J Med 2014, PMID 24897082) ran two identically-designed non-inferiority trials comparing once-weekly dalbavancin (day 1 and day 8) to daily vancomycin with an option to switch to oral linezolid, finding dalbavancin non-inferior with fewer treatment-related adverse events. A pediatric indication was added in 2021.

Safety

No boxed warning — a comparatively light label relative to telavancin's three-part warning. Labeled concerns include infusion-related reactions (similar to vancomycin's "red man syndrome," minimized with a slow 30-minute infusion) and rare hepatic transaminase elevations.

Current status

Still marketed, currently by AbbVie (via its Allergan subsidiary). Hospital/infusion-clinic use, no wellness or grey-market presence.

What you can do next

References

  1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW, "Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection," N Engl J Med 2014;370(23):2169-2179, PMID 24897082, DOI: 10.1056/NEJMoa1310480.
  2. FDA approval history for Dalvance (dalbavancin), 23 May 2014 (first QIDP-designated approval); pediatric indication, 2021.